Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is an established therapy for patients with type 2 diabetes that improves glucose control, induces weight loss, and reduces major adverse cardiovascular events. This evidence concerns the gene GCG and type 2 diabetes mellitus.